Press Releases and Publications

Press Releases

Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)

GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc. announced today that the US Food and Drug Administration (FDA) has given the company permission…

Galveston firm to test potential 'game-changer' in lung disease treatment

GALVESTON An island biopharmaceutical company has received U.S. Food and Drug Administration clearance for its first ever human tests of…

Galveston firm gets $10 million to study radiation antidote

By MYER LEE The Daily News  Dec 13, 2020  Darrell Carney’s company, Chrysalis BioTheraputics, received $10.4 million to continue developing…

Chrysalis BioTherapeutics Receives $10.4 Million From BARDA to Continue Development of TP508 as a Nuclear Countermeasure

December 01, 2020 09:10 AM Eastern Standard Time GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company focused on the…

Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development

Chrysalis BioTherapeutics Receives Additional Funding from the National Institutes of Health for COVID-19 Therapeutic Development GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc.,…

Chrysalis BioTherapeutics Receives Funding from the National Institutes of Health for COVID-19 Therapeutic Development

GALVESTON, Texas–(BUSINESS WIRE)–Chrysalis BioTherapeutics, Inc., a clinical-stage biotechnology company developing regenerative drugs for acute organ injury caused by radiation exposure,…

Drug developed by Galveston scientist to be tested for COVID-19 use

GALVESTON A drug developed by an independent biotech firm headquartered in Galveston will be tested for clinical application to problems…

TP508 Mitigates Radiation Induced GI Damage

Kantara, C., Moya, S.M., Houchen, C.W., Umar, S., Ullrich, R.L., Singh, P. and Carney, D.H. (2015) Novel regenerative peptide TP508…

Chrysalis BioTherapeutics Receives BARDA Contract for Over $10 million

GALVESTON, Texas, Aug. 27, 2019 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced that the Biomedical Advanced Research and Development Authority (BARDA), an agency…

Chrysalis BioTherapeutics Granted Orphan Drug Status for TP508

GALVESTON, Texas, Aug. 21, 2019 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced that the US Food and Drug Administration (FDA) Office of Orphan…

Chrysalis Biotherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development

GALVESTON, Texas, Feb. 7, 2017 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced initiation of a three-year $5.45 million contract with the National Institute of Allergy…

Nuclear Countermeasure Activity of TP508 Linked to Restoration of Endothelial Function and Acceleration of DNA Repair

Olszewska-Pazdrak B, McVicar, SD, Rayavara K, Moya SM, Kantara K, Gammarano C, Olszewska P, Fuller GM, Sower LE and Carney…

Chrysalis BioTherapeutics receives $3 million grant for nuclear countermeasure development

GALVESTON, TX, May 2, 2016. Chrysalis BioTherapeutics, Inc. today announced receipt of a $3 million grant from the National Institute…

New drug protects against the deadly effects of nuclear radiation 24 hours after exposure

An interdisciplinary research team led by The University of Texas Medical Branch at Galveston reports a new breakthrough in countering…

Chrysalis BioTherapeutics' TP508 Reverses Radiation-Induced GI Damage

GALVESTON, Texas, Aug. 18, 2015 /PRNewswire/ — Chrysalis BioTherapeutics, Inc. today announced publication of data demonstrating that TP508, the company’s lead drug…